Dentistry Section DOI : 10.7860/JCDR/2019/42597.13363
Year : 2019 | Month : Dec | Volume : 13 | Issue : 12 Page : ZE06 - ZE13

The Effect of Probiotic Administration in the Treatment of Peri-implant Diseases: A Systematic Review and Meta-analysis

Abdulaziz M Albaker1

1 Associate Professor, Department of Prosthetic Dental Science, College of Dentistry, King Saud University, Riyadh, Saudi Arabia.

NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR: Dr. Abdulaziz M Albaker, Associate Professor, Department of Prosthetic Dental Science, College of Dentistry, King Saud University, Riyadh PO Box 11545, Saudi Arabia.


According to the present evidence, there seems to be a variation with regards to the role of probiotics in the reduction of peri-implant inflammation and a systematic review is thought to be necessary to evaluate the clinical efficacy of probiotics compared with placebo in peri-implant disease.


To evaluate the clinical efficacy of probiotics in the treatment of peri-implant diseases.

Materials and Methods

Main electronic databases were explored until January 2019. Published articles measuring clinical efficacy of probiotics in any form with active intervention, placebo, or no treatment were considered. Probing Depth (PD), Bleeding on Probing (BOP) and Plaque Index (Pi) were selected as outcome variables. Meta-analysis reporting Weighted Mean Difference (WMD) and Odds Ratio (OR) of outcomes with 95% Confidence Intervals (CI).


Six clinical trials were included. Considering the overall effect of probiotics versus placebo in peri-implant mucositis, no significant differences were observed for PD (WMD=-0.11, 95% CI=-0.43;0.21, p=0.50), BOP (OR=1.03, 95% CI=0.40;2.62, p=0.94) and Pi (OR=0.80, 95% CI=0.29;2.18, p=0.66. In addition, the overall effect for PD (WMD=-0.25, 95% CI=-0.79;0.28, p=0.34), BOP (WMD=-0.44, 95% CI=-0.99;0.10, p=0.11) and Pi (WMD=-0.13, 95% CI=-0.67;0.40, p=0.62) in peri-implantitis was not statistically significant either.


Based on the qualitative and quantitative results of this review, the efficacy of probiotics in the treatment of peri-implant diseases remains debatable.


Peri-implant diseases are a group of inflammatory diseases that mainly affects the hard and soft tissues around the dental implants which are characterised by bleeding, redness and swelling of the gingiva along with deterioration of bone [1,2]. Peri-implant Mucositis (p-iM) is a prevalent, reversible condition which is associated with redness, swelling and bleeding of the gingival tissue around the implant without radiographic evidence of bone loss [3], and if left untreated, may lead to the development of Peri-Implantitis (PI), exhibiting loss of the supporting alveolar bone [4,5].

The gold standard treatment for peri-implant diseases includes professional plaque control by non-surgical Mechanical Debridement (MD) and oral home care that includes tooth brushing and use of chemical rinses [6]. Other adjunctive measures such as provision of local and systemic antibiotics, air abrasive devices and photodynamic therapy have also been proposed as new methods for greater results [7,8]. For definitive and proper management against the occurrence of disease, the consistent removal of the regular dental biofilm is of the primary concern that can be achieved with oral hygiene exercises, along with professional interventions. However, the mentioned treatment modalities, are not essentially helpful in treating peri-implantitis. Numerous surgical methods and decontamination procedures have been introduced for the treatment of peri-implantitis, but a consensus still has not been established regarding the optimal treatment protocol and there is less scientific evidence to prove which method is superior to the other [9].

With the development in the field of periodontics, new entities are being introduced which are playing an important role in the discovery of new and innovative methods of increasing plaque control and in detection of immune modulating factors. Recent studies have reported the use of probiotics which may effectively inhibit gingival inflammation, leading to reduction in peri-implant disease [10,11]. These mediators are ‘living bacteria when dispensed in suitable quantities in the host to offer health benefit’. Probiotics are known to exacerbate the commensal flora and prevents the settlement of the pathogenic bacteria which are associated with causation of the disease. The effect of probiotic involves different mechanisms including competitive exclusion of the harmful pathogens, immune modulation and impeding their adhesion to the substrate [12].

Recent research shows the use of different probiotics including Lactobacillus brevis (L. brevis) and Lactobacillus reuteri (L. reuteri) that have been assessed for their clinical efficacy in peri-implant disease [10,11]. According to the recent studies, these probiotics have a beneficial effect on the peri-implant inflammatory parameters. A Randomised Controlled Trial (RCT) by Flichy-Fernández A et al., reported substantial decrease in the cytokine levels and improvement in the peri-implant parameters and no change was observed in the placebo group, after probiotics use [10]. On the other hand, Hallström H et al., put forward comparable progress between probiotic and placebo groups at follow-up [11]. According to the present evidence, there seems to be a variation with regards to the role of probiotics in the reduction of peri-implant inflammatory parameters and a systematic review is thought to be necessary to evaluate the clinical efficacy of probiotics compared with placebo in peri-implant disease. The purpose of this systematic review was to evaluate the effect of probiotics compared with conventional intervention/placebo in patients with peri-implant diseases on peri-implant inflammatory parameters.

Materials and Methods

Study Protocol Registration

The present review was written in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines [13] and registered in the PROSPERO website ( database. The record was available online on November 12, 2018, registered as CRD42018110121.

PICOS Eligibility Criteria

Placebo-controlled, blinded, RCTs were included. Publication in language other than English were excluded.

Studies including ≥10 patients per group clinically diagnosed with peri-implant diseases (p-iM and/or PI) without any age restrictions.

Clinical efficacy of probiotics in any form with active intervention, placebo, or no treatment. Studies were included when they (i) tested one or more probiotics as an adjunct to Mechanical Debridement (MD) alone or with a placebo group and (ii) tested one or more probiotics in groups categorised according to health. Some of the included probiotics were, but not limited to Lactobacillus rhamnossus, Lactobacillus curvatus, Bifidobacterium animalis, Lactobacillus brevis, Lactobacillus reuteri, and Lactobacillus plantarum.

Probing Depth (PD) was the primary outcome. Secondary outcome measures included Bleeding on Probing (BOP) and/or Plaque Index (Pi). In the present review, only trials that reported any of these outcomes with a minimum follow-up of 4 weeks were included.

Electronic Database and Study Search

Following databases were explored; MEDLINE (1952-January 2019), EMBASE (1984-January 2019), Cochrane Central Register of Controlled Trials and Cochrane Oral Health Group Trials Register (1993-January 2019) for articles that focused the PICOS question using the following terms: ((Probiotics) OR (Lactobacillus reuteri) OR (Lactobacillus rhamnossus) OR (Lactobacillus curvatus) OR (Bifidobacterium animalis) OR (Lactobacillus brevis) OR (Lactobacillus plantarum) OR (yogurt) OR (tablets) OR (lozenges) AND ((peri-implant diseases) OR (peri-implantitis) OR (peri-implant mucositis) OR (inflammation) AND (plaque) OR (plaque scores) OR (plaque index) OR (bleeding) OR (bleeding on probing) OR (probing depth).

Titles of the main articles and their abstracts were screened. If primary variable was reported in the main abstract (or complete abstract missing), the article was selected for complete-text reviewing. If the complete-text article fulfilled the selection criteria, they were subsequently included in the review. Bibliography from research studies were manually hand searched to recognise studies that had gone unnoticed during the database searching in the following scientific journals: Clinical Oral Investigations, Journal of Periodontology, Acta Odontologica Scandinavica, Journal of Periodontal Research, Journal of Prosthodontic Research and Journal of Clinical Periodontology. Relevant studies that met the inclusion criteria were later used for data abstraction. The review process was planned and design in accordance with the PRISMA guideline [13].

Data Items and Abstractions

Data abstraction was performed according to several general and clinical characteristics including study design, demographics, potential confounders, probiotic administration, follow-up period, final study results and gingival inflammatory parameters.

Risk of Bias Across and within Individual Studies

Recommendations of the Consolidated Standards of Reporting Trials statement was used for assessing the risk of bias across the studies [14]. Risk of bias for individual study was estimated using the Cochrane Handbook for Systematic Reviews of Interventions [15]. Three scoring system including ‘high’, ‘low’ or ‘unclear’ were recorded for sections that had ‘high risk of bias’, ‘low risk of bias’ or ‘unclear risk of bias’, respectively. Overall, the studies were considered ‘high quality’ if all conditions met, ‘low quality’ if ≥1 condition did not meet, or ‘moderate quality’ if ≥1 condition was partly met.

Summary Measures and Approach to Quantitative Analysis

Meta-analysis was performed considering studies that reported the outcomes using L. reuteri only. Heterogeneity was estimated using the I2 and χ2 statistics. For considerable heterogeneity crossing over 50%, the random effects model was employed, or else the fixed effects model was used for heterogeneity ≤50% [16]. Heterogeneity was considered significant if p-value presented ≤0.05. Forest plots were plotted for Weighted Mean Difference (WMD) and 95% Confidence Intervals (CI) of main results. Data that could not be used for meta-analysis were described narratively.

Grading the ‘Body of Evidence’

Grading was performed for the included studies using the ‘Grading of Recommendations Assessment, Development and Evaluation’ (GRADE) [17]. The sections that were rated included biases, reliability of the results, integrity of evidence, accuracy and extent of the effect [18].


Search Results

A total of 2381 study titles and abstracts were initially identified. After removal of the duplicates (n=148), initial screening of titles and abstracts was performed, and 2221 articles were excluded that did not correspond to the PICO question. A total of 12 papers were selected for full-text reading. Of these 12 articles, six studies [10,11,19-22] were included and subsequently used for data extraction. The other six studies were excluded and not considered for this systematic review [Appendix-A]. All clinical trials were conducted in university hospitals. [Table/Fig-1] illustrates the study identification flow chart according to PRISMA with the reasons for exclusion of articles.

PRISMA flow diagram for studies retrieved through the searching and selection process.

General Description of Included Studies

All published studies were either double-blind [10,11,19,20] or triple-blind [21,22] placebo-controlled RCTs. Three studies were performed in Spain [10,21,22], while remaining three studies each were performed in Sweden [11], Italy [19], and Japan [20] respectively. The mean age of the included patients ranged from 53.7 years to 68.8 years. A total of 247 dental implants were examined for therapeutic effect. Probiotics were administered to 141 individuals, while a total of 106 individuals were administered placebo. Data on the overall percentage of female subjects ranged between 27% and 80%. Four studies included smokers [11,19,20,22], out of which one study evaluated the effects of probiotics in previously treated periodontitis cases and included photodynamic therapy [19]. Among the forms of probiotics used, five studies used lozenges for L. reuteri of dosage 1×108 Colony Forming Unit (CFU) and one study used the combination L. plantarum and L. brevis as powder form. Five studies [10,11,19,21,22] evaluated the treatment outcomes of probiotics in patients with p-iM, while two studies included patients having PI [20,21]. The follow-up duration ranged from 4 to 26 weeks from non-brushing period in the included studies. Two studies were funded by university while one study was funded by private laboratory [Table/Fig-2].

General characteristics of included studies in reversed chronological order.

Investigator et al.Study design; CountrySample size; Mean age in years; Female %; Number of dental implantsConfoundersType of probiotic administration; Frequency; DosageDisease type; Clinical inflammatory parameters studiedFollow-up (weeks)Study outcomesFunding source
Flichy-Fernández A et al., [10]Double-blind placebo controlled RCT; Spain12; 60.2; 58%; 54NALozenges- Lactobacillus reuteri ATCC PTA 5289 + DSM 17938; x1; 1×108 CFUp-iM: PD <4 mm with no evidence of bone lossPi, PDUp to 4Significant improvement in clinical inflammatory parameters for probiotic group at follow-upNot stated
Hallstörm H et al., [11]Double-blind placebo controlled RCT; SwedenProbiotic25; 53.7; 71%; 25Placebo24; 63.3; 56%; 24SmokersLozenges- Lactobacillus reuteri DSM 17938 + ATCC PTA 5289; x2; 1×108 CFUp-iM: PD ≥4 mm combined with bleeding and/or pus on probingBOP, Pi, PDUp to 26No statistical significant differences between test and control groups at follow-upUniversity funded
Mongardini C et al., [19]RCT cross over; Italy20; 57.0; 55%; 20Smokers; PDT; treated periodontitis casesPowder- Lactobacillus plantarum + Lactobacillus brevis; x1; NAp-iM: bone loss <2 mmPi, BOPUp to 6No statistical significant differences between test and control groups at follow-upPrivate funded
Tada H et al., [20]Double-blind placebo controlled RCT; JapanProbiotic15; 68.80; 80%; 15Placebo15; 65.87; 67%; 15Smokers; antibioticsLozenges- Lactobacillus reuteri DSM 17938 + ATCC PTA 5289; x2; 1×108 CFUPI: PD >4 and <7 mm with BOP and/or pus discharge and bone loss of >2 mmPD, BOPUp to 24No statistical significant differences between test and control groups at follow-upNot stated
Galofré M et al., [21]Triple-blind parallel-design RCT; SpainGroup- p-iMProbiotic11; 61.5; 45%; 11Placebo11; 60.0; 27%; 11Group- PIProbiotic11; 61.7; 64%; 11Placebo11; 56.8; 55%; 11NALozenges- Lactobacillus reuteri DSM 17938 + ATCC PTA 5289; x1; 1×108 CFUp-iM: inflamed mucosa with BOP and/or suppuration and no evidence of bone lossPI: BOP and/or suppuration, PD ≥5 mm and bone loss of ≥2 mmPi, BOP, PDUp to 13No statistical significant differences between test and control groups of p-iM at follow-upNo statistical significant differences between test and control groups of PI at follow-upNot stated
Peña M et al., [22]Triple-blind parallel-design RCT; SpainProbiotic25; 55.96; 68%; 25Placebo25; 61.16; 48%; 25SmokersLozenges- Lactobacillus reuteri (DSM 17938 + ATCC PTA 5289; x1; NAp-iM: presence of bleeding with gingival redness, swelling, and BOP without bone loss PD, Pi, BOPUp to 18No statistical significant differences between test and control groups at follow-upUniversity funded

BOP: Bleeding on probing; CFU: Colony forming unit; NA: Not available; PD: Probing depth; PDT: Photodynamic therapy; Pi: Plaque index; p-iM: Peri-implant mucositis; PI: Peri-implantitis; RCT: Randomised clinical trial

Clinical Peri-implant Parameters of the included Studies

Peri-implant mucositis

A total of 5 clinical trials reported data on PD [10,11,20-22] which ranged from 2.46 mm to 3.7 mm in the probiotics group and 2.47 mm to 3.5 mm for placebo groups at follow-up, respectively. Four RCTs [11,19,21,22] reported data on BOP out of which two trials [11,22] reported data as mean percentages and one study [19] reported BOP as median and interquartile ranges. Mean percentage of BOP ranged from 14% to 64% in the probiotics group, while mean percentage of BOP ranged from 17% to 60% in the placebo groups at follow-up, respectively. Five studies [10,11,19,21,22] reported data on Pi out of which two trials reported data as mean percentages and one trial reported data as median and interquartile ranges. Overall mean Pi of probiotics and placebo groups ranged from 0.25 to 0.96 and 0.29 to 1.09, while mean percentage Pi of probiotics and placebo groups ranged from 12% to 24% and 15% to 28% at follow-up, respectively [Table/Fig-3].

Clinical peri-implant outcomes of the included studies in chronological order.

Investigators et al., YearPocket depth (mm)Bleeding on probingPlaque index
Flichy-Fernández A et al., [10]ProbioticBaseline: 3.55±0.40Follow-up: 2.46±0.92*NAProbioticBaseline: 1.77±1.20Follow-up: 0.96±1.15*
PlaceboBaseline: 2.47±0.79Follow-up: 2.65±0.84PlaceboBaseline: 1.09±1.12Follow-up: 1.09±1.12
Hallstörm H et al., [11]ProbioticBaseline: 4.3±1.1Follow-up: 3.7±1.3*ProbioticBaseline: 54Follow-up: 14*ProbioticBaseline: 26Follow-up: 12*
PlaceboBaseline: 4.0±1.4Follow-up: 3.5±1.5PlaceboBaseline: 58Follow-up: 17*PlaceboBaseline: 32Follow-up: 15*
Mongardini C et al., [19]NAProbioticBaseline: 4 (3-6)Follow-up: 2 (0-2)*ProbioticBaseline: 1.2 (0.92-1.59)Follow-up: 0 (0.00-0.17)*
PlaceboBaseline: 3.5 (2-4)Follow-up: 2 (0-3)*PlaceboBaseline: 1.42 (0.92-1.75)Follow-up: 0.17 (0.00-0.33)*
Tada H et al., [20]ProbioticBaseline: 3.90±0.46Follow-up: 3.21±0.84*ProbioticBaseline: 3.20±1.26Follow-up: 1.53±1.41*ProbioticBaseline: 1.67±0.72Follow-up: 1.13±0.74*
PlaceboBaseline: 4.04±1.14Follow-up: 3.47±0.95*PlaceboBaseline: 3.67±1.59Follow-up: 2.33±1.95*PlaceboBaseline: 1.47±0.74Follow-up: 1.20±0.68
Galofré M et al., [21]Group- p-iMProbioticBaseline: 3.84±0.55Follow-up: 3.35±0.76*Group- p-iMProbioticBaseline: 0.61±0.27Follow-up: 0.29±0.09*Group- p-iMProbioticBaseline: 0.41±0.21Follow-up: 0.25±0.10*
PlaceboBaseline: 3.82±0.64Follow-up: 3.66±0.62PlaceboBaseline: 0.42±0.18Follow-up: 0.35±0.22PlaceboBaseline: 0.39±0.10Follow-up: 0.29±0.10*
Group- PIProbioticBaseline: 5.07±0.87Follow-up: 4.53±0.72*Group- PIProbioticBaseline: 0.53±0.23Follow-up: 0.33±0.09*Group- PIProbioticBaseline: 0.44±0.14Follow-up: 0.28±0.24*
PlaceboBaseline: 4.90±0.66Follow-up: 4.70±0.75PlaceboBaseline: 0.49±0.23Follow-up: 0.39±0.17PlaceboBaseline: 0.43±0.21Follow-up: 0.33±0.28*
Peña M et al., [22]ProbioticBaseline: 3.10±0.74Follow-up: 2.88±0.62*ProbioticBaseline: 100Follow-up: 64*ProbioticBaseline: 72Follow-up: 24*
PlaceboBaseline: 3.32±0.65Follow-up: 2.98±0.60*PlaceboBaseline: 100Follow-up: 60*PlaceboBaseline: 68Follow-up: 28*

*Indicates intra-group statistical significance, p-iM: Peri-implant mucositis; PI: Peri-implantitis, Values reported in percentage, Values reported in median and interquartile range


For peri-implantitis, a total of 2 clinical trials [20,21] reported PD which ranged from 3.2 mm to 4.5 mm in the probiotics group and 3.47 mm to 4.7 mm in the placebo group at follow-up, respectively. Data for BOP ranged from 0.33 to 1.53 in the probiotic group and 0.39 to 2.33 in the placebo group at follow-up. Plaque index was also reported in the same RCTs which ranged from 0.28 to 1.13 in the probiotic group and 0.33 to 1.2 in the placebo group at follow-up, respectively [Table/Fig-3].

Risk of Bias Assessment Across Studies

All the clinical studies were subjected to critical analysis following the Cochrane Handbook for Systematic Reviews of Interventions for evaluating the risk of bias. The present authors classified four clinical trials [19-22] as having a low risk of bias and two clinical trials [10,11] as having a high risk of bias. These four studies were judged to have lower risk of bias due to adequate reporting of randomisation technique, sequence generation, blinding and patients withdrawal. In contrast the domain classified as having high risk of bias was sequence generation, allocation concealment, and unclear reporting of randomisation methods in two clinical trials [Table/Fig-4].

Risk of bias of the included studies.

InvestigatorsRandomization methodsSequence generationAllocation concealmentBlinding of study participants and personnelAll patients accounted for at the end of studyClear explanation of withdrawalsSelective reportingOver risk of bias
Flichy-Fernández A et al., [10]UnclearHighHighLowLowLowLowHigh
Hallstörm H et al., [11]LowHighLowLowLowLowUnclearHigh
Mongardini C et al., [19]LowLowLowLowLowLowLowLow
Tada H et al., [20]LowLowLowLowLowLowLowLow
Galofré M et al., [21]LowLowLowLowLowLowLowLow
Peña M et al., [22]LowLowLowLowLowLowLowLow

Main Outcome of the Studies

On intra-group analysis from the studies, all clinical studies showed that probiotic administration was effective in the treatment of peri-implant diseases at follow-up. After performing statistical meta-analysis, no statistical significant differences in the clinical peri-implant inflammatory parameters was observed between probiotics and placebo groups at follow-up for both peri-implant mucositis and peri-implantitis, respectively.

Meta-analysis was performed for quantitative data assessment. Only data presented for L. reuteri were analysed for clinical periodontal inflammatory parameters in meta-analysis.

Effect of probiotics in peri-implant mucositis

Considering the effects of probiotics on p-iM, 4 studies for PD [10,11,19,22], while only 2 studies for BOP and Pi presented data to be included in the meta-analysis [11,22]. The overall effect for PD was calculated as WMD, while Odds Ratio (OR) was calculated for both BOP and Pi, respectively, as their data was presented as numbers with positive outcomes. Fixed effect model was employed as there was no significant heterogeneity observed for PD (χ2=1.48, p=0.68, I2=0%), BOP (χ2=0.16, p=0.68, I2=0%) or Pi (χ2=0.0007, p=0.97, I2=0%). The overall effect for PD (WMD=-0.11, 95% CI=-0.43 to 0.21, p=0.50, [Table/Fig-5a]), BOP (OR=1.03, 95% CI=0.40 to 2.62, p=0.94, [Table/Fig-5b]) and Pi (OR=0.80, 95% CI=0.29 to 2.18, p=0.66, [Table/Fig-5c]) was not statistically significant between probiotics and placebo groups at follow-up.

Forest plot presenting post-therapy clinical peri-implant parameters by comparing probiotic therapy versus placebo in patients with peri-implant mucositis.

Effect of probiotics in peri-implantitis

Similarly, considering the effects of probiotics on PI, 2 studies [20,21] each for PD, BOP and Pi presented data to be included in the meta-analysis, respectively. The overall effect for PD, BOP and Pi was calculated by WMD. Fixed effect model was employed as there was no significant heterogeneity observed for PD (χ2=0.011, p=0.91, I2=0%), BOP (χ2=0.003, p=0.95, I2=0%) or Pi (χ2=0.02, p=0.87, I2=0%). The overall mean difference for PD (WMD=-0.25, 95% CI=-0.79 to 0.28, p=0.34, [Table/Fig-6a]), BOP (WMD=-0.44, 95% CI=-0.99 to 0.10, p=0.11, [Table/Fig-6b]) and Pi (WMD=-0.13, 95% CI=-0.67 to 0.40, p=0.62, [Table/Fig-6c]) was not statistically significant between probiotics and placebo groups at follow-up.

Forest plot presenting post-therapy clinical peri-implant parameters by comparing probiotic therapy versus placebo in patients with peri-implantitis.

Evidence Profile

The [Table/Fig-7] showes a summary of the various factors used to rate the quality of evidence and strength of recommendations according to GRADE. Taken together, the strength of a recommendation based on the quality of the evidence emerging from this review is estimated to be moderate. Given that the effect is small, the direction of recommendation emerging from this systematic review is weak in favour of the use of probiotics in the treatment of peri-implant diseases [Table/Fig-7].

Summary of findings table on body of the estimated evidence profile and appraisal of the strength of the recommendation regarding the effectiveness of probiotics on clinical peri-implant parameters in peri-implant diseases.

Determinants of qualityProbiotics
Study designRCTs
Number of studies n=6 [Table/Fig-1]Comparison n=87
Risk of biasLow
Consistency [Table/Fig-2 and 3]Rather not consistent
PrecisionRather precise
Publication bias (Appendices S1 and S2)No
Magnitude of the effectSmall
Strength of the recommendation based on the body of evidenceModerate
Direction of recommendationWeak in favour of the use of probiotics


Probiotic administration significantly improves clinical indices, (PD, BOp and pi) compared to placebo in peri-implant diseases, this was the hypothesis of the current review. Quantitatively, no statistical significant differences in the clinical peri-implant inflammatory parameters was observed between probiotics and placebo groups at follow-up for both peri-implant mucositis and peri-implantitis, respectively.

In the studies several inconsistencies with regards to the extent of disease were noted. There was either a lack of data or dissimilar case definitions applied for the diagnosis of p-iM and/or PI which may have produced bias in the treatment outcomes. Furthermore, in both probiotic and the placebo groups a significant improvement of the gingival parameters were detected (from the observation of the included studies). Furthermore, there were significant intragroup reduction of plaque scores between both the groups. The intragroup differences between the recruitment and the baseline visits may be hypothesised by the interim positive effect of the professional instructions and cleaning at the recruitment visit and the knowledge of the patients that they are being followed-up in a study. Moreover, part of these intragroup differences may probably be also because of the Hawthorne effect [23], in which the patients may have regulated oral home care more effectively or more consistently, although the participants were asked not to change their oral hygiene habits because they knew they were being observed in the clinical studies. Although only one study evaluated the Hawthorne effect among the patients [10], future studies are warranted to assess this effect.

Most of the RCTs included in the present review used lozenges as the mode of administration of probiotic in the treatment of peri-implant diseases. These studies which used lozenges form showed comparable improvements in clinical parameters with placebo. A possible clarification regarding this may lie in the ability of systemic delivery that crosses through liver and demonstrate low availability of the drug at the target site. In contrast, the competence of subgingival drug delivery to allow high drug concentrations and have controlled long-term release of the therapeutic agents at target sites (gingival sulcus) circumventing likely systemic adverse effects [24]. Although evidence regarding patients reporting adverse effects by the use of probiotics is sparse, this could prove favourable over systemic administration due to rapid absorption and low bioavailability in the body. Future studies are warranted to compare the efficacy of systemic versus local probiotics in peri-implant inflammation.

It is well-known that certain confounding factors such as smoking or periodontal diseases affect the local inflammation around teeth and dental implants. Such modifying factors were taken into consideration in some studies. Probiotic administration showed no statistically significant improvement in the clinical inflammatory parameters in patients receiving placebo. Although the smoking dose and duration was unclear, nevertheless, no regression analysis was performed in the clinical trial to control the effect of smoking habit on peri-implant outcomes among the participants recruited which may result in significant bias in the included studies.

It is believed that true clinical benefits cannot only be gauged by clinical parameters, but it can be strengthened by incorporating surrogate measures like microbiological or immunological parameters. Although microbiological and immunological data was presented in the included studies (not reported in our systematic review); there was either a significant heterogeneity in the outcomes of these parameters, or there was a lack of quantitative data in the included studies. Such parameters could have given more evidence about the observed effect. It would be interesting to study in future trials about the colonisation and immunomodulation by probiotics in peri-implant diseases.

Less number of studies were the part of this present review which could be one of the limitations. The short follow-up duration in the included studies might not have produced in the assessed clinical indices. Furthermore, the selection criteria only considered articles in English language due to which bias may have resulted with potentially applicable studies published in other language being overlooked [25]. All these considerations, yet important factors may have caused discrepancies which make elucidations arduous and such results should be acknowledged with caution.


Based on the qualitative and quantitative results of this review, the efficacy of probiotics in the treatment of peri-implant diseases remains debatable. The body of evidence in the current review is limited. However, further well-designed RCTs using different strains of probiotics in broader population samples over longer periods of time are warranted to prove the effectiveness of probiotics in patients with peri-implant diseases. Furthermore, it would also be interesting to compare probiotics with different other interventions such as chlorhexidine and antibiotics.


[1]Derks J, Tomasi C, Peri-implant health and disease. A systematic review of current epidemiology J Clin Periodontol 2015 42:S158-S71.10.1111/jcpe.1233425495683  [Google Scholar]  [CrossRef]  [PubMed]

[2]Renvert S, Persson GR, Pirih FQ, Camargo PM, Peri-implant health, peri-implant mucositis, and peri-implantitis: Case definitions and diagnostic considerations J Clin Periodontol 2018 45:S278-S85.10.1111/jcpe.1295629926496  [Google Scholar]  [CrossRef]  [PubMed]

[3]Heitz-Mayfield LJ, Salvi GE, Peri-implant mucositis J Clin Periodontol 2018 45:S237-S45.10.1111/jcpe.1295329926488  [Google Scholar]  [CrossRef]  [PubMed]

[4]Dalago HR, Dalago HR, Schuldt Filho G, Rodrigues MA, Renvert S, Bianchini MA, Risk indicators for peri-implantitis. A cross-sectional study with 916 implants Clin Oral Implants Res 2017 28(2):144-50.10.1111/clr.1277226754342  [Google Scholar]  [CrossRef]  [PubMed]

[5]Salvi GE, Cosgarea R, Sculean A, Prevalence and mechanisms of peri-implant diseases Journal of Dental Research 2017 96(1):31-37.10.1177/002203451666748427680028  [Google Scholar]  [CrossRef]  [PubMed]

[6]Renvert S, Roos-Jansåker AM, Claffey N, Non-surgical treatment of peri-implant mucositis and peri-implantitis: A literature review J Clin Periodontol 2008 35:305-15.10.1111/j.1600-051X.2008.01276.x18724858  [Google Scholar]  [CrossRef]  [PubMed]

[7]Tavares LJ, Pavarina AC, Vergani CE, de Avila ED, The impact of antimicrobial photodynamic therapy on peri-implant disease: What mechanisms are involved in this novel treatment? Photodiagnosis Photodyn Ther 2017 17:236-44.10.1016/j.pdpdt.2016.11.01627939958  [Google Scholar]  [CrossRef]  [PubMed]

[8]Renvert S, Polyzois I, Treatment of pathologic peri-implant pockets Periodontol 2000 2018 76(1):180-90.10.1111/prd.1214929239086  [Google Scholar]  [CrossRef]  [PubMed]

[9]Renvert S, Polyzois IN, Clinical approaches to treat peri-implant mucositis and peri-implantitis Periodontol 2000 2015 68(1):369-404.10.1111/prd.1206925867993  [Google Scholar]  [CrossRef]  [PubMed]

[10]Flichy-Fernández A, Ata-Ali J, Alegre-Domingo T, Candel-Martí E, Ata-Ali F, Palacio J, The effect of orally administered probiotic Lactobacillus reuteri-containing tablets in peri-implant mucositis: a double-blind randomized controlled trial J Periodontal Res 2015 50(6):775-85.10.1111/jre.1226425712760  [Google Scholar]  [CrossRef]  [PubMed]

[11]Hallström H, Lindgren S, Widén C, Renvert S, Twetman S, Probiotic supplements and debridement of peri-implant mucositis: a randomized controlled trial Acta Odontol Scand 2016 74(1):60-66.10.3109/00016357.2015.104006525953193  [Google Scholar]  [CrossRef]  [PubMed]

[12]Teughels W, Loozen G, Quirynen M, Do probiotics offer opportunities to manipulate the periodontal oral microbiota? J Clin Periodontol 2011 38:159-77.10.1111/j.1600-051X.2010.01665.x21323712  [Google Scholar]  [CrossRef]  [PubMed]

[13]Moher D, Liberati A, Tetzlaff J, Altman DG, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Ann Intern Med 2009 151(4):264-69.10.7326/0003-4819-151-4-200908180-0013519622511  [Google Scholar]  [CrossRef]  [PubMed]

[14]Schulz KF, Altman DG, Moher D, CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials Ann Intern Med 2010 152(11):726-32.10.7326/0003-4819-152-11-201006010-0023220335313  [Google Scholar]  [CrossRef]  [PubMed]

[15]Higgins JP, Cochrane handbook for systematic reviews of interventions version 5.0.1 The Cochrane Collaboration http://www cochrane-handbook org. 200810.1002/9780470712184  [Google Scholar]  [CrossRef]

[16]Borenstein M, Hedges LV, Higgins JP, Rothstein HR, A basic introduction to fixed-effect and random-effects models for meta-analysis Res Synth Methods 2010 1(2):97-111.10.1002/jrsm.1226061376  [Google Scholar]  [CrossRef]  [PubMed]

[17]Guyatt GH, Oxman AD, Kunz R, Jaeschke R, Helfand M, Liberati A, Incorporating considerations of reis use into grading recommendations BMJ 2008 336(7654):1170-73.10.1136/bmj.39504.506319.8018497416  [Google Scholar]  [CrossRef]  [PubMed]

[18]Smiley CJ, Tracy SL, Abt E, Michalowicz BS, John MT, Gunsolley J, Evidence-based clinical practice guideline on the nonsurgical treatment of chronic periodontitis by means of scaling and root planing with or without adjuncts J Am Dent Assoc 2015 146(7):525-35.10.1016/j.adaj.2015.01.02626113100  [Google Scholar]  [CrossRef]  [PubMed]

[19]Mongardini C, Pilloni A, Farina R, Di Tanna G, Zeza B, Adjunctive efficacy of probiotics in the treatment of experimental peri-implant mucositis with mechanical and photodynamic therapy: a randomized, cross-over clinical trial J Clin Periodontol 2017 44(4):410-17.10.1111/jcpe.1268928032908  [Google Scholar]  [CrossRef]  [PubMed]

[20]Tada H, Masaki C, Tsuka S, Mukaibo T, Kondo Y, Hosokawa R, The effects of Lactobacillus reuteri probiotics combined with azithromycin on peri-implantitis: A randomized placebo-controlled study J Prosthodont Res 2018 62(1):89-96.10.1016/j.jpor.2017.06.00628756115  [Google Scholar]  [CrossRef]  [PubMed]

[21]Galofré M, Palao D, Vicario M, Nart J, Violant D, Clinical and microbiological evaluation of the effect of Lactobacillus reuteri in the treatment of mucositis and peri-implantitis: A triple-blind randomized clinical trial J Periodontal Res 2018 53(3):378-90.10.1111/jre.1252329352461  [Google Scholar]  [CrossRef]  [PubMed]

[22]Peña M, Barallat L, Vilarrasa J, Vicario M, Violant D, Nart J, Evaluation of the effect of probiotics in the treatment of peri-implant mucositis: a triple-blind randomized clinical trial Clin Oral Investig 2019 23(4):1673-83.10.1007/s00784-018-2578-830151705  [Google Scholar]  [CrossRef]  [PubMed]

[23]Sedgwick P, Greenwood N, Understanding the Hawthorne effect BMJ 2015 351:h467210.1136/bmj.h467226341898  [Google Scholar]  [CrossRef]  [PubMed]

[24]Greenstein G, Local drug delivery in the treatment of periodontal diseases: assessing the clinical significance of the results J Periodontol 2006 77(4):565-78.10.1902/jop.2006.05014016584336  [Google Scholar]  [CrossRef]  [PubMed]

[25]Egger M, Zellweger-Zähner T, Schneider M, Junker C, Lengeler C, Antes G, Language bias in randomised controlled trials published in English and German Lancet 1997 350(9074):326-29.10.1016/S0140-6736(97)02419-7  [Google Scholar]  [CrossRef]